Development of PARP Inhibitors for BRCA-Deficient Epithelial Ovarian Cancer

Eileen Parkes, Nuala McCabe, Richard Kennedy

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Recent trials of the poly(ADP-ribose) polymerase (PARP) inhibitors olaparib, rucaparib and niraparib have resulted in approval of these agents in ovarian cancer, initially in patients with germline BRCA1 or BRCA2 mutations, now extended to the maintenance setting for all platinum-sensitive ovarian cancer. PARP inhibitors were first developed as chemo-sensitising agents and early clinical trials focused on combination treatment with DNA-damaging chemotherapy. However, the identification of synthetic lethality of PARP inhibitor treatment in BRCA1 and BRCA2-mutant cancer led to trials in BRCA1/2-mutant ovarian cancer with clinical responses to single agent treatment. These DNA-repair targeted agents have been a success story of translational research. However, questions remain over their optimal use in ovarian cancer and the effectiveness of currently available predictive biomarkers.
LanguageEnglish
Title of host publicationOncogenomics: From Basic Research to Precision Medicine
EditorsFranco Dammacco
PublisherAcademic Press
Chapter36
Pages521-528
Number of pages8
Edition1
ISBN (Print)012811789, 9780128117866
Publication statusPublished - 05 Nov 2018

Fingerprint

Ovarian Neoplasms
Translational Medical Research
Platinum
DNA Repair
Therapeutics
Biomarkers
Maintenance
Clinical Trials
Drug Therapy
Mutation
Poly(ADP-ribose) Polymerase Inhibitors
Ovarian epithelial cancer
DNA
Neoplasms

Keywords

  • BRCA1
  • BRCA2
  • Ovarian cancer
  • Biomarker
  • DNA repair

Cite this

Parkes, E., McCabe, N., & Kennedy, R. (2018). Development of PARP Inhibitors for BRCA-Deficient Epithelial Ovarian Cancer. In F. Dammacco (Ed.), Oncogenomics: From Basic Research to Precision Medicine (1 ed., pp. 521-528). Academic Press.
Parkes, Eileen ; McCabe, Nuala ; Kennedy, Richard. / Development of PARP Inhibitors for BRCA-Deficient Epithelial Ovarian Cancer. Oncogenomics: From Basic Research to Precision Medicine. editor / Franco Dammacco. 1. ed. Academic Press, 2018. pp. 521-528
@inbook{a8ebf781b2a74e228fad1ab912456834,
title = "Development of PARP Inhibitors for BRCA-Deficient Epithelial Ovarian Cancer",
abstract = "Recent trials of the poly(ADP-ribose) polymerase (PARP) inhibitors olaparib, rucaparib and niraparib have resulted in approval of these agents in ovarian cancer, initially in patients with germline BRCA1 or BRCA2 mutations, now extended to the maintenance setting for all platinum-sensitive ovarian cancer. PARP inhibitors were first developed as chemo-sensitising agents and early clinical trials focused on combination treatment with DNA-damaging chemotherapy. However, the identification of synthetic lethality of PARP inhibitor treatment in BRCA1 and BRCA2-mutant cancer led to trials in BRCA1/2-mutant ovarian cancer with clinical responses to single agent treatment. These DNA-repair targeted agents have been a success story of translational research. However, questions remain over their optimal use in ovarian cancer and the effectiveness of currently available predictive biomarkers.",
keywords = "BRCA1, BRCA2, Ovarian cancer, Biomarker, DNA repair",
author = "Eileen Parkes and Nuala McCabe and Richard Kennedy",
year = "2018",
month = "11",
day = "5",
language = "English",
isbn = "012811789",
pages = "521--528",
editor = "Franco Dammacco",
booktitle = "Oncogenomics: From Basic Research to Precision Medicine",
publisher = "Academic Press",
edition = "1",

}

Parkes, E, McCabe, N & Kennedy, R 2018, Development of PARP Inhibitors for BRCA-Deficient Epithelial Ovarian Cancer. in F Dammacco (ed.), Oncogenomics: From Basic Research to Precision Medicine. 1 edn, Academic Press, pp. 521-528.

Development of PARP Inhibitors for BRCA-Deficient Epithelial Ovarian Cancer. / Parkes, Eileen; McCabe, Nuala; Kennedy, Richard.

Oncogenomics: From Basic Research to Precision Medicine. ed. / Franco Dammacco. 1. ed. Academic Press, 2018. p. 521-528.

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - Development of PARP Inhibitors for BRCA-Deficient Epithelial Ovarian Cancer

AU - Parkes, Eileen

AU - McCabe, Nuala

AU - Kennedy, Richard

PY - 2018/11/5

Y1 - 2018/11/5

N2 - Recent trials of the poly(ADP-ribose) polymerase (PARP) inhibitors olaparib, rucaparib and niraparib have resulted in approval of these agents in ovarian cancer, initially in patients with germline BRCA1 or BRCA2 mutations, now extended to the maintenance setting for all platinum-sensitive ovarian cancer. PARP inhibitors were first developed as chemo-sensitising agents and early clinical trials focused on combination treatment with DNA-damaging chemotherapy. However, the identification of synthetic lethality of PARP inhibitor treatment in BRCA1 and BRCA2-mutant cancer led to trials in BRCA1/2-mutant ovarian cancer with clinical responses to single agent treatment. These DNA-repair targeted agents have been a success story of translational research. However, questions remain over their optimal use in ovarian cancer and the effectiveness of currently available predictive biomarkers.

AB - Recent trials of the poly(ADP-ribose) polymerase (PARP) inhibitors olaparib, rucaparib and niraparib have resulted in approval of these agents in ovarian cancer, initially in patients with germline BRCA1 or BRCA2 mutations, now extended to the maintenance setting for all platinum-sensitive ovarian cancer. PARP inhibitors were first developed as chemo-sensitising agents and early clinical trials focused on combination treatment with DNA-damaging chemotherapy. However, the identification of synthetic lethality of PARP inhibitor treatment in BRCA1 and BRCA2-mutant cancer led to trials in BRCA1/2-mutant ovarian cancer with clinical responses to single agent treatment. These DNA-repair targeted agents have been a success story of translational research. However, questions remain over their optimal use in ovarian cancer and the effectiveness of currently available predictive biomarkers.

KW - BRCA1

KW - BRCA2

KW - Ovarian cancer

KW - Biomarker

KW - DNA repair

M3 - Chapter

SN - 012811789

SN - 9780128117866

SP - 521

EP - 528

BT - Oncogenomics: From Basic Research to Precision Medicine

A2 - Dammacco, Franco

PB - Academic Press

ER -

Parkes E, McCabe N, Kennedy R. Development of PARP Inhibitors for BRCA-Deficient Epithelial Ovarian Cancer. In Dammacco F, editor, Oncogenomics: From Basic Research to Precision Medicine. 1 ed. Academic Press. 2018. p. 521-528